iiinova — where your digital self keeps evolving

BLOODPAC @bloodpac.bsky.social · 15/09/2026

📅 Save the date! Join BLOODPAC's New Frontiers Seminar: Molecular Residual Disease in Hematologic Cancers: Progress, Challenges, and Future Directions 🗓 Dec. 9, 2026 ⏰ 1–3 PM ET 💻 Virtual #MRD #LiquidBiopsy #HemeOnc

000

BLOODPAC @bloodpac.bsky.social · 10/09/2026

Day 2 of BLOODPAC’s Q3 2026 Meeting is underway! Today’s agenda features presentations highlighting new insights and developments across liquid biopsy. We’re grateful to our Working Group Co-Chairs and members whose leadership drives BLOODPAC’s collaborative work! Thank you @tempusai.bsky.social!

010

BLOODPAC @bloodpac.bsky.social · 09/09/2026

Day 1 is a wrap! Our working groups had a productive day of discussion and collaboration, followed by insightful presentations this evening. Thank you to our members, co-chairs, speakers, and @tempusai.bsky.social for a great first day. We’re looking forward to tomorrow!

010

BLOODPAC @bloodpac.bsky.social · 09/09/2026

BLOODPAC’s Q3 2026 Meeting is underway in Chicago! Today, our members are diving into working group sessions focused on advancing key priorities across the liquid biopsy field, with presentations and discussion continuing into the evening. Thank you to @tempusai.bsky.social for hosting us!"

000

BLOODPAC @bloodpac.bsky.social · 02/09/2026

Just one week until BLOODPAC’s Q3 2026 in-person meeting! We look forward to welcoming members and collaborators to Chicago on September 9–10 for two days of discussion, collaboration, and progress across BLOODPAC initiatives.

000

BLOODPAC @bloodpac.bsky.social · 01/09/2026

Please join us in welcoming Josep Carreras Leukaemia Research Institute (IJC) as BLOODPAC’s newest member! IJC is a biomedical research institute focused on advancing research & innovation in blood cancers. Learn more: www.carrerasresearch.org/en/

000

BLOODPAC @bloodpac.bsky.social · 27/08/2026

“I’ve been with BLOODPAC for about eight years, and we’re just starting a clinical utility working group focused on MRD. If you’re interested in helping us advance MRD testing for patients, please join us.” A Q1 takeaway from Girish Putcha. Looking ahead to Q3 in September. #LiquidBiopsy #MRD

000

BLOODPAC @bloodpac.bsky.social · 26/08/2026

Please join us in welcoming @stemcell.com as BLOODPAC’s newest member! STEMCELL develops cell culture media, cell separation technologies, instruments, & resources supporting research in stem cell biology, immunology, cancer, regenerative medicine, and cellular therapy. Learn more: www.stemcell.com

020

BLOODPAC @bloodpac.bsky.social · 26/08/2026

Only two weeks until BLOODPAC’s Q3 2026 in-person meeting! Join us September 9–10 in Chicago, hosted by @tempusai.bsky.social, as members and collaborators come together to advance collaborative efforts across the liquid biopsy field.

000

BLOODPAC @bloodpac.bsky.social · 25/08/2026

Please join us in welcoming Claret Bioscience as BLOODPAC’s newest member! Claret develops next-generation sequencing library preparation and analysis tools supporting research applications involving degraded DNA and RNA. Learn more: www.claretbio.com

000

BLOODPAC @bloodpac.bsky.social · 20/08/2026

"We’re seeing collaboration across industry, diagnostics, pharma, academia, and regulatory partners that isn’t possible anywhere else—bringing the liquid biopsy ecosystem together with a shared goal of patient impact.” —Darya, Q1 BLOODPAC Meeting. #LiquidBiopsy Looking ahead to Q3 in September.

000

BLOODPAC @bloodpac.bsky.social · 20/08/2026

000

BLOODPAC @bloodpac.bsky.social · 18/08/2026

Please join us in welcoming @cellcarta.bsky.social as BLOODPAC’s newest member! CellCarta is a global CRO providing precision medicine testing services & biomarker solutions, with capabilities spanning immune monitoring, proteomics, genomics, digital pathology, & more. Learn more: cellcarta.com

000

BLOODPAC @bloodpac.bsky.social · 13/08/2026

"This is my first visit to BLOODPAC, and I think it’s an amazing organization. Everyone here is benefiting from what’s happening in the scientific world—understanding regulations and working toward solutions that will help people, especially in diagnostics.” —Alex Chauhan Looking forward to our Q3!

000

BLOODPAC @bloodpac.bsky.social · 12/08/2026

One month to go! BLOODPAC’s Q3 2026 in-person meeting takes place September 9–10 in Chicago, hosted by @tempusai.bsky.social. We’re looking forward to discussions, project updates, and connecting with colleagues from across the liquid biopsy community.

000

BLOODPAC @bloodpac.bsky.social · 07/08/2026

"The whole industry is coming together to make a difference—advancing patient care through better access to and higher-quality blood-based testing in oncology. It's a real pleasure to be part of.” —Barnaby Balfour, Q1 BLOODPAC Meeting. Looking ahead to Q3 in September. #LiquidBiopsy #Collaboration

000

BLOODPAC @bloodpac.bsky.social · 04/08/2026

We're pleased to welcome @bloodcancerunited.bsky.social to BLOODPAC! Blood Cancer United is a global nonprofit focused on blood cancer patient support, research, and advocacy. We look forward to collaborating to advance liquid biopsy innovation for patients. Learn more: bloodcancerunited.org

110

BLOODPAC @bloodpac.bsky.social · 28/07/2026

🎥 This video takes us back to our 2022 Summit, celebrating 5 years of BLOODPAC. Now we’re gearing up for 2027… and the progress since then has been incredible. Collaboration is accelerating cancer innovation through shared data, standards, and a common mission. www.youtube.com/watch?v=OQnq...

youtube.com

The BLOODPAC Story

YouTube video by BLOODPAC

010

BLOODPAC @bloodpac.bsky.social · 22/07/2026

Great discussion at the 5th Liquid Biopsy for Precision Oncology East Coast! BLOODPAC's Executive Director Lauren Leiman joined Jon Baden (BMS) and Duane Hassane (AZ) for an interactive session on MRD, standardization, and advancing clinical adoption through collaboration. #LiquidBiopsy #MRD

000

BLOODPAC @bloodpac.bsky.social · 22/07/2026

We're live today at the 5th Liquid Biopsy for Precision Oncology Summit East Coast! Join BLOODPAC at 11:30 AM ET for an interactive discussion on advancing the clinical integration of liquid biopsy through global collaboration. See you there! #LiquidBiopsy

000

BLOODPAC @bloodpac.bsky.social · 15/07/2026

Just one week until the 5th Liquid Biopsy for Precision Oncology Summit East Coast! Join BLOODPAC on July 22 for an interactive session on advancing liquid biopsy through global collaboration, harmonized standards, and shared best practices. #LiquidBiopsy #PrecisionOncology

000

BLOODPAC @bloodpac.bsky.social · 09/07/2026

We're excited to welcome Brian to the BLOODPAC team! 🎉 With 20+ years of experience in data science, bioinformatics, software engineering, and AI/ML, Brian joins us after leadership roles at GT Molecular and Sunbird Bio. Welcome to BLOODPAC, we're so glad you're here!

010

BLOODPAC @bloodpac.bsky.social · 08/07/2026

Join BLOODPAC at the 5th Liquid Biopsy for Precision Oncology Summit East Coast on July 22! Our Executive Director will share BLOODPAC's impact in MRD, followed by an interactive panel on building global consensus to advance the clinical integration of liquid biopsy. #LiquidBiopsy #PrecisionOncology

000

BLOODPAC @bloodpac.bsky.social · 07/07/2026

BLOODPAC’s Q3 2026 in-person meeting is approaching! Hosted by @tempusai.bsky.social in Chicago, the meeting will bring together members from across the liquid biopsy ecosystem to share insights, discuss projects, and strengthen collaboration. See you in September!

000

BLOODPAC @bloodpac.bsky.social · 17/06/2026

BLOODPAC welcomes @clearnotehealth.bsky.social as our newest member. ClearNote Health develops blood-based technologies for cancer detection and precision medicine using a proprietary 5hmC-epigenomic platform that combines biology and AI. Learn more: www.clearnotehealth.com

000

BLOODPAC @bloodpac.bsky.social · 11/06/2026

Welcome to BLOODPAC's newest member, the Institute for Follicular Lymphoma Innovation (IFLI). Founded in 2022, IFLI supports research focused on follicular lymphoma biology, biomarker discovery, MRD, data-driven approaches, and emerging therapies. Learn more: www.i-fli.org

000

BLOODPAC @bloodpac.bsky.social · 09/06/2026

Save the date! BLOODPAC’s Q3 2026 in-person meeting will take place September 9–10 in Chicago, hosted by @tempusai.bsky.social. We look forward to bringing together members and collaborators to share updates and advance the liquid biopsy field through collaboration.

000

BLOODPAC @bloodpac.bsky.social · 02/06/2026

Save the date 📍 BLOODPAC’s 10-Year Anniversary In-Person Summit is coming to Washington, D.C. on March 4, 2027. We’re bringing together our community to reflect on a decade of progress and continue advancing liquid biopsy—together. Plan to join us March 3–5. More details coming soon.

011

BLOODPAC @bloodpac.bsky.social · 28/05/2026

#ICYMI our ED, Lauren Leiman joined Believe in Progress: An #AACR Foundation Podcast as a guest, alongside Mary Royal, and hosted by Mitch Stoller. 🎧 From lived experience to advancing liquid biopsy + MRD—worth a listen: www.youtube.com/watch?v=Nb3o...

youtube.com

070: The Cancer Test Most Patients Don't Know Exists: BLOODPAC

YouTube video by American Association for Cancer Research

000

BLOODPAC @bloodpac.bsky.social · 26/05/2026

We’re pleased to welcome @zymoresearch.bsky.social as the newest member of BLOODPAC! Zymo Research develops molecular biology products and services supporting sample collection and preservation, DNA/RNA purification, epigenetics, microbiomics, and NGS research applications.

010

BLOODPAC @bloodpac.bsky.social · 22/05/2026

‼️We’re hiring! BLOODPAC is seeking a Program Lead, Scientific Strategy & Policy to help advance initiatives in liquid biopsy, regulatory science, health policy, and diagnostics strategy. Join us in shaping the future of cancer diagnostics. #Reimbursement #Coverage #Payers #healthpolicy

000

BLOODPAC @bloodpac.bsky.social · 21/05/2026

What started as a collaborative effort to bring clarity to early detection terminology is now one of the top viewed articles in @ascptclinpharm.bsky.social Clinical and Translational Science. Huge thanks to our first co-authors and the entire ED&S WG. More work on MCED standards ahead!

011

BLOODPAC @bloodpac.bsky.social · 20/05/2026

We’re pleased to welcome @adaptivebiotech.bsky.social as the newest member of BLOODPAC! Adaptive Biotechnologies advances immune-driven medicine through technologies that support MRD assessment in blood cancer across clinical care and biopharma research, and immune profiling for clinical research.

000

BLOODPAC @bloodpac.bsky.social · 14/05/2026

We’re pleased to welcome Countable Labs as the newest member of BLOODPAC. Their Countable PCR platform is designed for applications including liquid biopsy, MRD monitoring, ctDNA quantification, and rare variant detection. Learn more at countablelabs.com

000

BLOODPAC @bloodpac.bsky.social · 12/05/2026

🙌 Our updated paper on generic analytical validation protocols for NGS-based #ctDNA assays is published in JCO PO! Built from years of real-world use + community feedback, this Version 2.0 reflects our commitment to keeping these resources relevant. Read it here 👉 ascopubs.org/doi/10.1200/...

010

BLOODPAC @bloodpac.bsky.social · 06/05/2026

Our Executive Director Lauren Leiman joined Believe in Progress: An @theaacr.bsky.social Foundation Podcast (hosted by Mitch Stoller) with Mary Royal to discuss liquid biopsy—from early detection to MRD. 🎧 Listen to the full episode here: www.youtube.com/watch?v=Nb3o...

020

BLOODPAC @bloodpac.bsky.social · 04/05/2026

000

BLOODPAC @bloodpac.bsky.social · 30/04/2026

Looking ahead to IQN Path Annual Meeting in May - our Executive Director will present on advancing collaboration to accelerate implementation, highlighting BLOODPAC initiatives and Global Regulatory Working Group efforts. Join us in Naples!

010

BLOODPAC @bloodpac.bsky.social · 23/04/2026

Our Executive Director will be traveling to Naples, Italy this May to attend IQN Path’s Annual Meeting. Her talk will highlight BLOODPAC’s mission and key initiatives, with a special focus on the Global Regulatory Working Group’s efforts.

000

BLOODPAC @bloodpac.bsky.social · 21/04/2026

Thank you to everyone who joined us for the @bloodpac.bsky.social community reception during the #AACR26 Annual Meeting. 🙌It was great to connect with colleagues across the liquid biopsy community and keep the conversation on early detection going. #AACR26 #LiquidBiopsy #EarlyDetection #BLOODPAC

000

BLOODPAC @bloodpac.bsky.social · 20/04/2026

Thank you to everyone who made BLOODPAC’s #AACR26 session a success! From our speakers to a packed room, this work matters. 🙌Special thanks to our co-chairs Christina Clarke Dur (Grail) & Bree Mitchell (Natera) and the #AACR team for all their support. #LiquidBiopsy #EarlyDetection

000

BLOODPAC @bloodpac.bsky.social · 18/04/2026

#AACR26 is in full swing, and BLOODPAC’s early detection session is today! Join @theaacr.bsky.social and @bloodpac.bsky.social for a discussion on one of the key challenges facing blood-based cancer early detection tests. 📅 Apr 18 | 2:30–4 PM 🔗 www.abstractsonline.com/pp8/#!/21436...

020

BLOODPAC @bloodpac.bsky.social · 17/04/2026

How should we interpret performance metrics for blood-based early cancer detection tests? Join the @theaacr.bsky.social and @bloodpac.bsky.social @ #AACR26 for a session on clearer frameworks and more meaningful approaches to evaluating test performance. 🔗 www.abstractsonline.com/pp8/#!/21436...

000

BLOODPAC @bloodpac.bsky.social · 15/04/2026

Join the @theaacr.bsky.social and @bloodpac.bsky.social at #AACR26 for 𝘾𝙤𝙣𝙩𝙚𝙭𝙩𝙪𝙖𝙡 𝘾𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙚𝙨 𝙞𝙣 𝙄𝙣𝙩𝙚𝙧𝙥𝙧𝙚𝙩𝙞𝙣𝙜 𝙋𝙚𝙧𝙛𝙤𝙧𝙢𝙖𝙣𝙘𝙚 𝙤𝙛 𝘽𝙡𝙤𝙤𝙙-𝘽𝙖𝙨𝙚𝙙 𝙀𝙖𝙧𝙡𝙮 𝘾𝙖𝙣𝙘𝙚𝙧 𝘿𝙚𝙩𝙚𝙘𝙩𝙞𝙤𝙣 𝙏𝙚𝙨𝙩𝙨: 𝘼 𝘽𝙇𝙊𝙊𝘿𝙋𝘼𝘾 𝙋𝙚𝙧𝙨𝙥𝙚𝙘𝙩𝙞𝙫𝙚 🔗 www.abstractsonline.com/pp8/#!/21436...

011

BLOODPAC @bloodpac.bsky.social · 10/04/2026

Join Lauren Leiman, our ED, for an upcoming webinar with Twist Bioscience and The Scientist: Beyond the Bottleneck: Engineering Sensitive Bespoke MRD Assays 🗓 April 13 | ⏰ 3:30 PM ET Experts will discuss challenges + new approaches in tumor-informed MRD testing. 🎧 Register: bit.ly/4sQEE9r

bit.ly

Beyond the Bottleneck: Engineering Sensitive Bespoke MRD Assays | The Scientist

In this roundtable webinar, discover how scientists improve tumor-informed minimal residual disease (MRD) testing for real-time monitoring.

000

BLOODPAC @bloodpac.bsky.social · 09/04/2026

AACR is around the corner, and BLOODPAC is bringing the early detection conversation to the stage. Join BLOODPAC at #AACR26 to discuss evolving approaches for evaluating single- and multi-cancer detection tests and the implications for clinical use. 🗓️Apr 18 | 2:30–4 PM

000

BLOODPAC @bloodpac.bsky.social · 08/04/2026

Our tumor-informed MRD protocols paper is featured on the JCO Precision Oncology Conversations podcast! Grateful to JCO Precision Oncology for amplifying this work and advancing the conversation around MRD. 🎧 Listen here: ascopubs.org/do/jco-po-ar...

ascopubs.org

JCO PO Article Insights: Analytical Validation of Tumor-Informed ctDNA Assays for MRD | Podcast | ASCO Publications

In this JCO PO Article Insights episode, host Jordan Goldstein summarizes the article,

021

BLOODPAC @bloodpac.bsky.social · 07/04/2026

One month since our Q1 meeting hosted by @guardanthealth.bsky.social in San Diego! Whether advancing key deliverables or exploring what’s next for BLOODPAC, the conversations were engaging, productive, and full of energy. #BLOODPAC #LiquidBiopsy

000

BLOODPAC @bloodpac.bsky.social · 02/04/2026

How do we evaluate performance for blood-based cancer early detection tests? Join BLOODPAC at #AACR26 for presentations + panel discussion exploring single- and multi-cancer detection test performance, real-world prevalence, and emerging standards. 🗓️Apr 18 | 2:30–4 PM

000

BLOODPAC @bloodpac.bsky.social · 26/03/2026

We’re bringing a stellar lineup to BLOODPAC’s early detection session at #AACR26. Hear from experts shaping how we define and interpret performance for blood-based cancer early detection tests. 📅 Apr 18 ⏰ 2:30–4 PM

000